Thailand’s fight for national sovereignty - the issue of compulsory licenses Since coup Sept 2006, the new interim government issued compulsory licenses.

Slides:



Advertisements
Similar presentations
Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,
Advertisements

1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
Understanding patents & medicine access the WTO, free trade agreements & patent law.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
Using FTA Side Letters and Congressional Letters to Authorize Waiver of Data Exclusivity and Linkage Professor Brook K. Baker Northeastern U. School of.
J.P. Singh Georgetown University Communication, Culture, & Technology Program TRIPS: Negotiating Intellectual Property in the World Trading System J.
Patent Pools Increasing access to Medicines and Innovation Ellen ‘t Hoen MSF Access to Essential Medicines Campaign Barcelona 9 Dec
The Global Access to Medicines Movement Peter Maybarduk April 15, 2011.
Ms. Josie Chetty: Senior Pharmacist, MOH Mr. Reginald Hoareau & Mr. Ronny Arnephy: NGO Representatives.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.
A revised framework for global medicine access Sanjay Basu Reblaw X.
Intellectual Property Rights, Services and Trade Facilitation CARSTEN FINK African/LDCs Ambassadors Seminar on Post-Hong Kong Assessment of the Doha Round,
Can we create a global trade framework for health care R&D that puts patients first? James Love Consumer Project on Technology Washington, DC Presented.
1 Licensing Agreements and the Protection of Intellectual Property Chapter 17 © 2005 Thomson/West Legal Studies In Business.
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
A very short introduction to patents & access to medicines.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
Community Views on Intellectual Property as a Barrier to Access UNITAID Meeting – 4th OCT Sarah Zaidi, International Treatment Preparedness Coalition.
Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Thailand, TRIPS, and Compulsory Licensing Tanyaporn Wansom Global Health Chair, American Medical Student Association 2006 WHO Duke University.
Common themes TRIPS flexibilities – Assertion and erosion of flexibilities – Legal and regulatory reform – Use of flexibilities: opposition has generated.
 .
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
TRIPS plus FTAs Rohit Malpani Oxfam America. Public health consequences of TRIPS plus FTAs Prospective studies on FTAs with TRIPS plus provisions –US.
TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.
WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,
1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.
Global Patent Debate K.Ravi Srinivas May 12-13, 2011.
Zimbabwe CSOs TRIPS and Access to medicines Aulline Mabika-Chapisa.
Ideas in Development The Potential Impact of WTO Accession, FTAs and Partnership & Cooperation Agreements (PCAs) on Access to Medicines.
Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.
Page 1 Implementation of the WTO Decision on TRIPS and Public Health Government of Canada August 2004.
The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
Intellectual Property Rights and Pharmaceuticals (Case study- Novartis’s claim in India) Background note prepared for PHM Vic Internet Workshop.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
TRIPS+ provisions in FTAs and the implications for access to medicines Sanya Smith Third World Network 27 August 2005.
UNCTAD/CD-TFT 1 IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade.
Agreement on TRIPS TRIPS Agreement  When the WTO was established, it led to 18 specific agreements to which all members need to adhere. Members necessarily.
The introduction of compulsory licenses for essential medicines in Thailand Sripen Tantivess International Health Policy Program, Ministry of Public Health,
Alexandra Heumber Médecins Sans Frontières Access to Essential Medicines Campaign DEBRIEFING WHA May 2006.
Ellen ‘t Hoen Médecins sans Frontières
Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.
Tensions between Brazil and the United States
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.
Access to ARVs in Brazil: challenges for civil society XVII International Aids Conference Satellite Meeting on Access to Medicines and Intellectual Property.
Access to AIDS Treatment and Intellectual Property Rights’ Protection in Thailand Jiraporn Limpananont, Associate Professor Dr. at Social Pharmacy Research.
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.
NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.
TRADE NEGOTIATION ON PHARMACETICALS PRESENTED BY CHOGO,MALESO (092SIS10).
Patents & Public Health
WTO and medicines: from Doha to Cancún
Intellectual Property Protection and Access to Medicines
Access to Generic Medicines The Use of Compulsory Licensing
Access to Treatment: People Before Trade
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
Béchir N’Daw, UNAIDS Secretariat
IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade Agreements.
Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.
Presentation transcript:

Thailand’s fight for national sovereignty - the issue of compulsory licenses Since coup Sept 2006, the new interim government issued compulsory licenses for three key drugs in the treatment of HIVAIDS and heart disease

Background to announcements of CL 2002 Thaksin’s new government introduces universal health care – for 30 baht Thailand developed ARV drug cocktail for $31 per month ($490 branded drugs). By 2006 increasing need for second generation ARV drugs (WHO recommends seven, five of which are currently patented). Thailand has 20,000 new cases of HIVAIDs a year 2006 political & social unrest with Thaksin regime – nepotism, corruption, brutal suppression of muslim minority in South & selling of Thai assets.

Thaksin Government negotiated 8 FTA’s & by Sept. 06 Thailand in 6 th round of negotiations with US for FTA Much internal opposition to US negotiations within agriculture sector (jasmin rice patent fear) and health sector (TRIPS) & the nature of the negotiations + no public debate (as per Thai Constitution), + negotiations were in English + pressure for signing before lapse of US Trade Promotion Act (July 07) Thai FTA Watch website - strength of opposition to US FTA. php?t=14&s_id=47&d_id=47 php?t=14&s_id=47&d_id=47

Strong networking networking between US & Thai AIDS organizations – Oct 06 Thai Network of People living with HIVAIDS conducted a campaign tour of 29 US cities at the time the 6 th round of Thai-US FTA negotiations thru US AIDS Organizations’ support. History of US pharmaceutical industry via USTR meddling Thailand since Susannah Markandya July 23, thailand.html thailand.html

The CL for Plavix (heart disease) is a strategic move – as Thailand is in epidemiological transition as mortality rates from non- communicable diseases have over taken communicable diseases woap.html woap.html 3.htm The CL for Plavix is taking the debate on ‘public health emergencies” re Doha declaration on TRIPS to another level - the first time a developing country used compulsory licensing to challenge patents for a 'life-style' disease — one that is not for AIDS or an epidemic.

Public Health at Risk: A US Free Trade Agreement could threaten access to medicines in Thailand. Oxfam Briefing Paper No 86 althbp86_thailand.htm Highlights stringent drug patent and marketing rules (that exceed WTO standards) being negotiated in Free Trade Agreement (FTA) between US & Thailand, limiting competition and access to affordable medicines jeopardizing the future of the successful Thai HIV/AIDS treatment programmes, which relies on inexpensive generic drugs. READ

WHO – ?an about face since WHO Commission on Intellectual Property Rights Report New DG. Dr Chan, criticized Thailand for not negotiating with drug companies before issue of CL Reiterates crucial role of drug companies BUT WHY THE CRITICISM? USA makes extensive use of CL. & has not negotiated with drug companies before CL inplace (James Love of Knowledge Ecology International) html (People’s Daily) html Thailand’s move is in accordance with Doha Declaration on TRIPS & CL ruling!

The issue of the sovereign right of states to utilize the Doha Declaration to secure access to medicines will continue … Novartis has taken the Indian Govt to court – will Abbott or Bristol Myers Squibb to takeThai Government to court, and WHO seems unduly influenced by US & pharmaceutical co. The power of networking for petitions Contacting our Federal MP’s –re clarification of Australia’s commitment to Doha Decl. and promoting WHO IP Plan Is Govt. direction to Jane Halston as Aust. Member of WHO Exec committee one of promoting the WHO IPR Plan? What role can PHMOz play?